#1 Clinical Trials Search in Europe

Autologous Adipose-Derived Stem Cells

A groundbreaking clinical trial is exploring the use of autologous adipose-derived stem cells, specifically the NVD-003 osteogenic bone graft, to treat congenital pseudarthrosis of the tibia (CPT) in pediatric patients. This innovative approach aims to address a challenging condition that affects bone healing in children, offering hope for improved outcomes and quality of life.

Table of Contents

What is NVD-003?

NVD-003 is a new medical treatment that uses autologous adipose-derived stem cells. In simple terms, these are stem cells taken from a patient’s own fat tissue. This treatment is being developed as an osteogenic bone graft, which means it’s designed to help form new bone tissue.[1]

The treatment is currently being studied as an implant, which means it’s surgically placed directly where it’s needed in the body. NVD-003 is classified under the category of drugs used for the treatment of bone diseases.[1]

What Medical Condition Does NVD-003 Treat?

NVD-003 is being studied to treat a condition called congenital pseudarthrosis of the tibia (CPT) in children. Let’s break this down:

  • Congenital means the condition is present at birth
  • Pseudarthrosis means “false joint” – it’s when a bone doesn’t heal properly after a break
  • Tibia is the larger of the two bones in the lower leg

So, CPT is a rare condition where a child is born with a tendency for their shin bone (tibia) to break and not heal properly, forming a “false joint” instead of solid bone.[1]

How Does NVD-003 Work?

NVD-003 works by using the patient’s own stem cells to help form new bone. Here’s a simple breakdown of the process:

  1. Doctors collect a small amount of fat tissue from the patient. This is called adipose tissue collection (ATC).
  2. The stem cells are extracted from this fat tissue and specially prepared in a laboratory.
  3. These prepared stem cells are then surgically implanted at the site of the bone problem. This is called the grafting surgery (GS).
  4. The stem cells are expected to help form new bone tissue, potentially healing the “false joint” and creating a normal, solid bone.[1]

Current Clinical Trial for NVD-003

NVD-003 is currently being studied in a clinical trial. This trial is described as a “proof of concept” study, which means it’s an early-stage trial to see if the treatment works as expected. The main goals of this trial are:

  • To check if NVD-003 is safe to use in children with CPT
  • To see how well NVD-003 works in forming new bone and healing the “false joint”
  • To monitor any side effects or complications from the treatment[1]

Who is Eligible for the NVD-003 Clinical Trial?

The trial is looking for specific types of patients. Here are some of the main criteria:

  • Children aged 2 to 8 years old
  • Diagnosed with congenital pseudarthrosis of the tibia
  • Have had no more than 2 previous failed surgeries to treat the CPT
  • Weigh at least 5 kg (about 11 pounds)
  • Are in generally good health and able to undergo surgery[1]

There are also several conditions that would prevent a child from participating in the trial, such as having certain infections, allergies, or other medical conditions. A doctor involved in the study would need to review each child’s specific situation to determine if they’re eligible.[1]

Safety and Efficacy Measures

The researchers will be closely monitoring the patients to ensure the treatment is safe and to see how well it works. They’ll be looking at:

  • Short-term safety: Any side effects or problems that occur within the first 3 months after the grafting surgery
  • Mid-term safety: Any issues that arise between 3 and 12 months after surgery
  • Long-term safety: Any problems that occur between 12 and 24 months after surgery
  • Efficacy: How well the bone is forming, joining, and remodeling. This will be checked using special scans (CT scans and X-rays) at various time points after the surgery.[1]

Potential Benefits of NVD-003

While it’s important to remember that NVD-003 is still in the testing phase, the researchers hope it could offer several benefits:

  • Improved bone healing for children with CPT
  • Potentially fewer surgeries needed compared to current treatments
  • Using the child’s own cells, which might reduce the risk of rejection
  • Improved quality of life for children with CPT, including better mobility and less pain[1]

It’s crucial to note that these potential benefits are still being studied, and more research is needed to confirm the safety and effectiveness of NVD-003.

Aspect Details
Treatment NVD-003 (Autologous Adipose-Derived Stem Cells)
Condition Congenital Pseudarthrosis of the Tibia (CPT)
Patient Age Range 2-8 years
Primary Objectives Short-term, mid-long-term, and long-term safety assessment
Secondary Objectives Efficacy in bone formation, union, and remodeling
Follow-up Duration Up to 24 months post-grafting surgery
Key Assessments CT scans, X-rays, Clinical Global Impression scales

FAQ

  • What is congenital pseudarthrosis of the tibia (CPT)? Congenital pseudarthrosis of the tibia is a rare bone condition in children where the shin bone (tibia) fails to heal properly after a fracture, leading to a false joint or persistent non-union.
  • How does the NVD-003 treatment work? NVD-003 is an autologous osteogenic bone graft made from the patient's own fat-derived stem cells. It is implanted at the site of the bone defect to promote bone formation, union, and remodeling.
  • Who is eligible for this clinical trial? The trial is open to children aged 2-8 years with CPT, weighing at least 5kg, who have had no more than two previous failed surgical interventions to treat the primary CPT fracture.
  • What are the main objectives of the study? The primary objectives are to assess the short-term, mid-long-term, and long-term safety of the NVD-003 treatment. Secondary objectives include evaluating its efficacy in bone formation, union, and remodeling.
  • How long will patients be monitored after the treatment? Patients will be monitored for up to 24 months after the grafting surgery to assess long-term safety and efficacy of the NVD-003 treatment.

Ongoing Clinical Trials on Autologous Adipose-Derived Stem Cells

  • Study of NVD003 stem cell implant compared to bone graft for children with congenital pseudarthrosis of the tibia

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Spain

  • Study on the Safety and Effectiveness of NVD-003 Implant for Adults with Difficult-to-Heal Lower Leg Bone Fractures

    Recruiting

    2 1 1
    Investigated drugs:
    Belgium Luxembourg

  • Study on NVD-003 Bone Graft for Treating Congenital Pseudarthrosis of the Tibia in Children

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

Glossary

  • Autologous: Derived from the patient's own body, in this case, the stem cells are taken from the patient's own fat tissue.
  • Adipose-Derived Stem Cells: Stem cells extracted from fat tissue that have the potential to develop into various cell types, including bone cells.
  • Congenital Pseudarthrosis of the Tibia (CPT): A rare bone condition present at birth where the shin bone (tibia) fails to heal properly after a fracture, forming a false joint.
  • Osteogenic: Capable of producing or forming bone tissue.
  • Bone Graft: A surgical procedure that replaces missing bone with material from the patient's own body, a donor, or synthetic alternatives to help repair bone defects.
  • NVD-003: The specific autologous osteogenic bone graft product being tested in this clinical trial for treating CPT.
  • Paley Type 3 or 4 Fracture: Classification of CPT fractures based on their severity and characteristics, as defined by Dr. Dror Paley.
  • Remodeling: The process by which bone adapts to stresses and changes in the body, involving the continuous removal and formation of bone tissue.
  • CT-scan: Computed Tomography scan, an imaging technique that provides detailed cross-sectional images of bones and other body structures.
  • Clinical Global Impression (CGI): A standardized assessment tool used by healthcare professionals to evaluate a patient's overall clinical progress and treatment response.

References

  1. http://clinicaltrials.eu/trial/study-on-nvd-003-bone-graft-for-treating-congenital-pseudarthrosis-of-the-tibia-in-children/